Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 63

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 63
---
 Meeting.

Listing of New ParentCo Common Stock

Shares of ParentCo Common Stock and ParentCo Public Warrants are expected to be listed on the Nasdaq Global Market under the market value standard, under the symbols “LIMN” and “LIMNW”, respectively. At the Effective Time, we expect ParentCo will satisfy all of the initial listing requirements under the market value standard; however, we currently do not meet the Round Lot Requirement. We have engaged a securities market advisory firm to assist with obtaining the requisite number of round lot stockholders to satisfy the Round Lot Requirement before the Business Combination is consummated.

Representations and Warranties and Covenants

Each of the parties to the Business Combination Agreement have made representations, warranties and covenants in the Business Combination Agreement that are customary for transactions of this nature.

<div align='center'>3</div>

TABLE OF CONTENTS

Conditions to Each Party’s Obligations

Consummation of the transactions contemplated by the Business Combination Agreement is subject to customary conditions of the respective parties, and conditions customary to special purpose acquisition companies, including the approval of Iris’s stockholders and Liminatus’s members. In addition, consummation of the Transactions is subject to other closing conditions, including, among others: (a) if required, the expiration of the waiting period (or extension thereof) under the HSR Act, (b) the absence of any order, writ, judgment, injunction, temporary restraining order, stipulation, determination, decree or award entered by or with or under the authority of any governmental entity or arbitral institution in effect enjoining or prohibiting the consummation of the Transactions, and the absence of any law that makes consummation of the Transactions illegal or otherwise prohibited, (c) approval by Iris’s stockholders at the Special Meeting of the Transactions, the adoption of the Incentive Plan, and the appointment of members of the ParentCo Board, (d) the registration statement of which this proxy statement/prospectus is a part shall have become effective, no stop order shall have been issued by the SEC and remain in effect and no proceeding seeking such a stop order shall have been threatened or initiated by the SEC and remain pending, (e) receipt of approval for listing on Nasdaq for the shares of ParentCo Common Stock to be issued in connection with the Mergers, which condition cannot be waived without recirculation or resolicitation of this proxy statement or prospectus, (f) delivery by the other parties of all